Outlook Therapeutics Statistics
Share Statistics
Outlook Therapeutics has 24.91M shares outstanding. The number of shares has increased by 91.39% in one year.
| Shares Outstanding | 24.91M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 5.28% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 16.04M |
| Failed to Deliver (FTD) Shares | 1.50K |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 4.13M, so 17.47% of the outstanding shares have been sold short.
| Short Interest | 4.13M |
| Short % of Shares Out | 17.47% |
| Short % of Float | 27.13% |
| Short Ratio (days to cover) | 1.26 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -2.44.
| PE Ratio | 0 |
| Forward PE | -2.44 |
| PS Ratio | 0 |
| Forward PS | 1 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Outlook Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.64, with a Debt / Equity ratio of 0.
| Current Ratio | 0.64 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | -2336747.89 |
| Interest Coverage | -22.71 |
Financial Efficiency
Return on equity (ROE) is 1.03% and return on capital (ROIC) is 98.12%.
| Return on Equity (ROE) | 1.03% |
| Return on Assets (ROA) | -2.61% |
| Return on Capital (ROIC) | 98.12% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -3,140.30B |
| Employee Count | 24 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 2.80B |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -70.76% in the last 52 weeks. The beta is 0.63, so Outlook Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.63 |
| 52-Week Price Change | -70.76% |
| 50-Day Moving Average | 3.68 |
| 200-Day Moving Average | 6.51 |
| Relative Strength Index (RSI) | 48.02 |
| Average Volume (20 Days) | 1.84M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -71,703.20B |
| Net Income | -75,366.70B |
| EBITDA | -71,703.20B |
| EBIT | n/a |
| Earnings Per Share (EPS) | -4063.16 |
Balance Sheet
The company has 14.93M in cash and 29.74M in debt, giving a net cash position of -14.81M.
| Cash & Cash Equivalents | 14.93M |
| Total Debt | 29.74M |
| Net Cash | -14.81M |
| Retained Earnings | -543,284.90B |
| Total Assets | 47.09M |
| Working Capital | 3.06M |
Cash Flow
In the last 12 months, operating cash flow was -68,793.90B and capital expenditures 0, giving a free cash flow of -68,793.90B.
| Operating Cash Flow | -68,793.90B |
| Capital Expenditures | 0 |
| Free Cash Flow | -68,793.90B |
| FCF Per Share | -3708.8 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OTLK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -181391.07% |
| FCF Yield | -123449578.91% |
Analyst Forecast
The average price target for OTLK is $31.4, which is 1301.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $31.4 |
| Price Target Difference | 1301.8% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Mar 14, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Mar 14, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -15.93 |
| Piotroski F-Score | 2 |